DaVita (DVA) – Analysts’ Weekly Ratings Changes

DaVita (NYSE: DVA) recently received a number of ratings updates from brokerages and research firms:

• 7/14/2026 – DaVita had its price target raised by Truist Financial Corporation from $205.00 to $250.00. They now have a “hold” rating on the stock.
• 7/10/2026 – DaVita had its price target raised by UBS Group AG from $235.00 to $270.00. They now have a “buy” rating on the stock.
• 7/8/2026 – DaVita had its price target raised by Barclays PLC from $194.00 to $218.00. They now have an “equal weight” rating on the stock.
• 7/6/2026 – DaVita was downgraded by Zacks Research from “strong-buy” to “hold”.
• 6/8/2026 – DaVita had its “hold (c+)” rating reaffirmed by Weiss Ratings.

Insiders Place Their Bets

In other DaVita news, insider Kathleen Alyce Waters sold 15,405 shares of DaVita stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the completion of the sale, the insider owned 109,194 shares of the company’s stock, valued at approximately $22,756,029.60. The trade was a 12.36% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Joel Ackerman sold 51,471 shares of the stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $192.10, for a total value of $9,887,579.10. Following the completion of the transaction, the chief financial officer directly owned 132,434 shares in the company, valued at $25,440,571.40. This represents a 27.99% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 1.90% of the stock is owned by insiders.

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.